Roche Holding’s (NASDAQ:RHHBY) oncology portfolio is its largest therapeutic area, and Avastin is one of its top selling drugs. However, it is expected to lose market exclusivity this year, and Pfizer’s Zirabev, a biosimilar to Avastin, was recently approved by the U.S. FDA, while it was already …
Source: Forbes Markets
